This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis (NVS) Gets FDA Nod for Cosentyx's Label Expansion
by Zacks Equity Research
The FDA approves Novartis' (NVS) Cosentyx for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis.
Novartis (NVS) to Buy Gyroscope, Submits Herceptin Biosimilar to EMA
by Zacks Equity Research
Novartis (NVS) is set to acquire ocular gene therapy company Gyroscope Therapeutic. Generic arm Sandoz submits a marketing authorization application for a proposed biosimilar of Herceptin.
Novartis (NVS) Collaborates With BeiGene for Oncology Drug
by Zacks Equity Research
Novartis (NVS) signs collaboration and license agreement with BeiGene for ociperlimab (BGB-A1217), expanding research and development activities in immuno-oncology.
Ionis (IONS) Collaborates With AstraZeneca for Eplontersen
by Zacks Equity Research
Ionis (IONS) and AstraZeneca (AZN) are set to have joint development and commercialization rights of eplontersen in the United States. AstraZeneca will have exclusive rights to commercialize it in the rest of the world.
Novartis (NVS) Highlights Growth Profile at its R&D Day
by Zacks Equity Research
Novartis (NVS) throws light on its pipeline progress, key areas of focus and long-term targets at its R&D day. Here, we discuss key highlights from the same.
Aurinia (AUPH) Stock Up on Potential Acquisition Rumors
by Zacks Equity Research
Aurinia (AUPH) gains on rumors of a potential acquisition yet again. Reportedly, the company is being eyed by Novartis.
Deciphera (DCPH) to Prioritize Key Pipeline Drugs, Cut Jobs
by Zacks Equity Research
Deciphera (DCPH) announces a corporate restructuring plan to prioritize development of vimseltinib and DCC-3116, streamline commercial operations and reduce workforce by almost 35%. Shares rise.
Bristol Myers' (BMY) Plaque Psoriasis Drug Filings Get Through
by Zacks Equity Research
Bristol Myers' (BMY) applications seeking approval for deucravacitinib are accepted by the regulatory bodies of both the United States and the European Union.
Deciphera (DCPH) Down More Than 70% in Past 3 Months: Here's Why
by Zacks Equity Research
Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.
Ligand's (LGND) Drug-Developing Technologies Holds Potential
by Zacks Equity Research
Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.
Deciphera (DCPH) Gets EU Nod for Qinlock in Fourth-Line GIST
by Zacks Equity Research
The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.
Ionis (IONS) Q3 Earnings & Revenues Fall Short of Estimates
by Zacks Equity Research
Ionis (IONS) incurs wider-than-expected Q3 loss. The company maintains its top-and bottom-line guidance for 2021
Incyte (INCY) Q3 Earnings & Sales Beat, Royalty Revenues Grow
by Zacks Equity Research
Incyte (INCY) beats earnings and sales estimates in the third quarter on higher royalty revenues and increased Jakafi sales.
Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab
by Kinjel Shah
Several big drugmakers announce third-quarter 2021 earnings. An FDA panel votes in favor of Pfizer's (PFE) COVID-19 vaccine for use in kids 5 to 11 years of age.
Alnylam's (ALNY) Q3 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Alnylam's (ALNY) earnings and sales miss estimates in the third quarter of 2021. The company reiterates its financial guidance for 2021. Stock down.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Visa, Novartis, Advanced Micro Devices and Deere
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Visa, Novartis, Advanced Micro Devices and Deere
Q3 Earnings Scorecard & Analyst Reports for Berkshire Hathaway, Visa & Novartis
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Visa Inc. (V), and Novartis AG (NVS).
Will Higher Jakafi Sales Boost Incyte's (INCY) Q3 Earnings?
by Zacks Equity Research
Incyte's (INCY) third-quarter 2021 earnings are likely to have gained from higher Jakafi sales as patients resume visits to the doctors.
Company News for Oct 27, 2021
by Zacks Equity Research
Companies in The news Are: UPS,WM,ARCC,NVS
Novartis (NVS) Q3 Earnings Beat, Sandoz Under Strategic Review
by Zacks Equity Research
Novartis (NVS) reports mixed results in the third quarter, as key brands maintain momentum but generics business remains weak.
Regeneron (REGN) Dupixent Meets Goal in Prurigo Nodularis Study
by Zacks Equity Research
Regeneron's (REGN) phase III study on Dupixent for treating adults with uncontrolled prurigo nodularis meets its primary and all secondary endpoints.
The Zacks Analyst Blog Highlights: Alphabet, Netflix, Thermo Fisher Scientific, Wells Fargo and Novartis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Netflix, Thermo Fisher Scientific, Wells Fargo and Novartis
Top Stock Reports for Alphabet, Netflix & Thermo Fisher
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Netflix, Inc. (NFLX), and Thermo Fisher Scientific Inc. (TMO).
Deciphera (DCPH) Thrives on Qinlock, Overdependence a Woe
by Zacks Equity Research
Deciphera's (DCPH) Qinlock is approved for treating advanced gastrointestinal stromal tumors. The drug has seen solid uptake since its launch. Heavy dependence on Qinlock for growth remains a concern.
bluebird (BLUE) Gives Details on Oncology Business Spinoff
by Zacks Equity Research
bluebird (BLUE) provides information on stock distribution ratio and cash allocation for the planned spin-off of the oncology business.